Navigation Links
Studies assess genetics, modified treatment to improve outcomes, reduce toxicity
Date:12/8/2012

a treatment associated with both short- and long-term toxicities.

ALL, the most common form of leukemia in children, is a fast-growing cancer of the white blood cells in which the bone marrow makes a large number of abnormal white blood cells that are unable to develop and fight infection. Important developments over the past 20 years have led to seminal insights about ALL in children, and today nearly 90 percent of children diagnosed with standard-risk ALL are cured. Some treatment regimens for standard-risk ALL include initial infusions of daunorubicin, a type of anthracycline. While effective, continual use of this therapy is associated with potential long-term heart damage, leading researchers to assess whether eliminating or reducing the dosage of daunorubicin during the initial one-month induction therapy period might provide the same level of efficacy as the standard treatment protocol with reduced long-term risk.

In order to assess the efficacy of ALL treatment without daunorubicin during induction therapy, a team of researchers from 20 centers across France and one center in Belgium initiated a multicenter Phase III clinical trial in which 1,128 pediatric patients with standard-risk B-cell ALL were randomized into two treatment arms. Arm A included 560 patients who received a standard dose of daunorubicin during induction therapy, while Arm B included 568 patients who did not receive initial therapy with daunorubicin. Both groups received doxorubicin during delayed intensification (last treatment phase before reaching maintenance) and a standard protocol of 24-month maintenance therapy from December 2000 to June 2010, during which five-year event-free survival (EFS) and overall survival (OS) were assessed.

For those patients treated with daunorubicin, the five-year EFS rate was 92.9 percent, compared to 93.3 percent in the non-daunorubicin arm. Overall survival rates were 97.2 percent and 98.2 percent in the daunorubicin and n
'/>"/>

Contact: Andrea Slesinski
aslesinski@hematology.org
614-352-5096
American Society of Hematology
Source:Eurekalert

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. John Theurer Cancer Center to present 37 studies at the 2012 ASH Annual Meeting
2. Benefit6 Whole Body Protection, a New Product by I Do Strive LLC, Provides Increased Energy Production According to Recent Studies
3. Sharp spike in computer-related injuries predicted for medical workers, find studies
4. Analysis of conflicting fish oil studies finds that omega-3 fatty acids still matter
5. Studies from 2012 Quality Care Symposium highlight findings in improving quality of cancer care
6. New studies show effects of mammography guideline changes
7. 2 NIH studies show power of epidemiology research; Underscore need to address health disparities
8. Scripps studies show community-based diabetes programs are key to lowered costs and improved care
9. Cancer Drug Reduced Relapses in MS Patients: Studies
10. University of Houston India Studies Program presents Circuits of Empire: India as Metropole
11. Studies Show Limits, Promise of Laser Removal of Tattoos
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Minn. (PRWEB) January 22, 2015 Blue Cross ... those Minnesotans who exemplify what it means to “Live Fearless.” ... chance for people to share their stories about how they ... or simply inspired others by living in the moment. By ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Juvent Sports ... at the 2015 PGA Merchandise Show to bestow a ... incredible female amateur golfer, Arlene McKitrick. The award commemorated ... amateur golf tournament win. She won her first amateur ...
(Date:1/22/2015)... January 22, 2015 Autocarinsurancebest.com has released a ... a commercial auto insurance policy . , Auto insurance ... vehicles. It is no longer necessary to call an agent ... now available online on a single website: http://autocarinsurancebest.com/ . ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Joan Lunden, ... keynote speaker at the upcoming 32nd Annual Miami ... Physicians’ Education Resource®, LLC (PER®) , shares that ... have gone undetected if she had not followed up ...
(Date:1/22/2015)... January 23, 2015 Recently, Weddingshe.com has added ... and has announced its highest annual revenues in the past ... its popular glamorous wedding dresses. , According to the sales ... wedding dress promotions for them in 2015. This point can ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2
... kidney transplant recipients need to take immunosuppressive drugs for the ... the thousands who have undergone transplantation, have been able to ... studying these rare individuals have identified a pattern of genes ... day be used to help identify other transplant recipients who ...
... about beta blockers making COPD worse are unfounded, experts ... tradition says that the beta blockers used to treat ... have severe lung disease, but a new Dutch study ... more than 2,200 people with chronic obstructive pulmonary disease ...
... ... President and Chief Executive Officer, is a finalist for the Ernst & Young Entrepreneur of ... ... Pentec Health Incorporated announced today that Joe Cosgrove, President and Chief Executive Officer, is ...
... Medicine for the first time have determined that bone marrow ... the bone marrow a potential therapeutic target, especially in people ... of the respiratory tract, cells produced by the bone marrow ... help fight infection. The data are published in the current ...
... University ... Mind Project. The Developing Mind Project aims to discover fundamentals of early learning and ... ... Learning & Brain Sciences (I-LABS) today announced the launch of a multi-year, multimillion-dollar initiative ...
... ... offered leadership and guidance about the transition from paper to electronic medical records for ... was held in mid-May. , ... Dearborn, MI (Vocus) May 24, 2010 -- Secure-24 and ATMP offered leadership ...
Cached Medicine News:Health News:Gene pattern may identify kidney transplant recipients who don't need lifelong anti-rejection drugs 2Health News:Gene pattern may identify kidney transplant recipients who don't need lifelong anti-rejection drugs 3Health News:Heart Drugs Safe for Lungs, Study Finds 2Health News:Heart Drugs Safe for Lungs, Study Finds 3Health News:Joseph Cosgrove Named as E&Y Entrepreneur Of The Year Finalist in the Greater Philadelphia Region 2Health News:Joseph Cosgrove Named as E&Y Entrepreneur Of The Year Finalist in the Greater Philadelphia Region 3Health News:Mount Sinai discovers bone marrow plays critical role in enhancing immune response to viruses 2Health News:University of Washington Institute for Learning & Brain Sciences Launches Developing Mind Project 2Health News:University of Washington Institute for Learning & Brain Sciences Launches Developing Mind Project 3Health News:University of Washington Institute for Learning & Brain Sciences Launches Developing Mind Project 4Health News:ATMP and Secure-24 Offer Physicians Leadership and Guidance for Electronic Medical Records 2Health News:ATMP and Secure-24 Offer Physicians Leadership and Guidance for Electronic Medical Records 3
(Date:1/22/2015)... 2015  ResMed Inc. (NYSE: RMD ) today announced ... the quarter was $423.0 million, a 10 percent increase compared ... increase on a constant currency basis). Net income was $91.2 ... ended December 31, 2013. Diluted earnings per share for the ...
(Date:1/22/2015)... 2015  Profil Institute for Clinical Research, Inc., a clinical ... today a new textbook,  Translational Research Methods for Diabetes, ... leading global scientific publisher. The textbook is ... use in early phase clinical studies of new drugs ...
(Date:1/22/2015)... ( http://www.researchandmarkets.com/research/w25xpc/allergy ) has announced the addition of ... by End User - Global Forecast to 2019" report ... market is valued at $1,228.58 million in 2014 and is ... $2,230.72 million by 2019. Allergy diagnostics is used to determine ...
Breaking Medicine Technology:ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 2Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 3
... Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD ... following a final approval from the US Food ... New Drug Application (ANDA) for generic Acular® opthalmic ... This strength of ketorolac is therapeutically equivalent to ...
... Althea Technologies, Inc., a leading provider of ... the addition of customized Formulation Development to the ... by the newly appointed Dr. James Matsuura, Director ... team of formulation and analytical scientists, along with ...
Cached Medicine Technology:Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Opthalmic Solution 2Althea Technologies Adds Formulation Development to Its Integrated Offering of Contract Services 2
... The NOW® Malaria Test is a field or ... Malaria infection. It is intended for the detection ... and an antigen that is common to all ... (P.f.), Plasmodium vivax (P.v.), Plasmodium ...
... Central Station provide an example of the ... cath or electrophysiology lab to healthcare professionals ... providing both physiomonitoring parameters and electronic charting ... on its own network. Witts Central Station ...
For the critical care environment, telemetry, emergency room and other monitoring areas....
DS 7600 Central Station...
Medicine Products: